Abstract:An enzymatic method has been successfully established enabling the generation of partially base-modified RNA (previously named RZA) constructs, in which all G residues were replaced by isomorphic fluorescent thienoguanosine ( th G) analogs, as well as fully modified RZA featuring th G, 5-bromocytosine, 7-deazaadenine and 5-chlorouracil. The transcriptional efficiency of emissive fully modified RZA was found to benefit from the use of various T7 RNA polymerase variants. Moreover, d th G could be incorporated into PCR products by Taq DNA polymerase together with the other three base-modified nucleotides. Notably, the obtained RNA products containing th G as well as th G together with 5-bromocytosine could function as effectively as natural sgRNAs in an in vitro CRISPR-Cas9 cleavage assay. N 1 -Methylpseudouridine was also demonstrated to be a faithful non-canonical substitute of uridine to direct Cas9 nuclease cleavage when incorporated in sgRNA. The Cas9 inactivation by 7-deazapurines indicated the importance of the 7-nitrogen atom of purines in both sgRNA and PAM site for achieving efficient Cas9 cleavage. Additional aspects of this study are discussed in relation to the significance of sgRNA–protein and PAM–-protein interactions that were not highlighted by the Cas9–sgRNA–DNA complex crystal structure. These findings could expand the impact and therapeutic value of CRISPR-Cas9 and other RNA-based technologies. Nucleobase modifications enzymatically incorporated into the CRISPR-Cas9 system revealed the tolerance of Cas9 to m1Ψ- and fluorescent th G-modified sgRNA and requirements for PAM recognition. With the advent of CRISPR-Cas9 gene editing, we now have to hand a simple two-component system amendable to silencing and knock-in editing effectively any gene. Yet we must not forget that the implications of immunotoxicity along with the poor stability and specificity of canonical nucleic acids hold enormous challenges for in vivo applications, especially in gene therapy. Our study endorses the feasibility of the enzymatic approach to incorporate nucleobase modifications into the CRISPR-Cas9 system unveiling the tolerance of Cas9 to N 1 -methylpseudouridine (m1Ψ)- and emissive thienoguanosine ( th G)-modified sgRNA as well as thus far uncharted structural requirements for ensuring proper PAM recognition.

Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity

High-frequency off-target mutagenesis induced by CRISPR/Cas9 in Arabidopsis and its prevention by improving specificity of the tools

Targeting Specificity of the CRISPR/Cas9 System.

Computationally Engineered CRISPR-SpyCas9 High-Fidelity Variants with Improved Specificity and Reduced Non-specific DNA Damage

Specificity of CRISPR/Cpf1 on single-nucleotide mismatched target sites

Molecular Mechanism of D1135E-Induced Discriminated CRISPR-Cas9 PAM Recognition

Chimeric CRISPR guides enhance Cas9 target specificity

Selection of extended CRISPR RNAs with enhanced targeting and specificity

CRISPR-Cas9 recognition of enzymatically synthesized base-modified nucleic acids

Molecular basis for the PAM expansion and fidelity enhancement of an evolved Cas9 nuclease

A small PAM optimises target recognition in the CRISPR-Cas immune system

PAM-Flexible Genome Editing with an Engineered Chimeric Cas9.

Paving the way towards precise and safe CRISPR genome editing

Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants

Engineered CRISPR-Cas9 nuclease with expanded targeting space

Deleting Specific Residues From the HNH Linkers Creates A CRISPR-SpCas9 Variant With High Fidelity and Efficiency

Recent Advances in Improving Gene-Editing Specificity through CRISPR–Cas9 Nuclease Engineering

Precision in Action: The Role of Clustered Regularly Interspaced Short Palindromic Repeats/Cas in Gene Therapies

Screening DNA Aptamers That Control the DNA Cleavage, Homology-Directed Repair, and Transcriptional Regulation of the CRISPR-(d)Cas9 System.

Effect of the Phosphoryl Guanidine Modification in Chimeric DNA-RNA crRNAs on the Activity of the CRISPR-Cas9 System In Vitro

Engineered CRISPR-Cas9 nucleases with altered PAM specificities